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ABSTRACT
My laboratory studies the cytokine named TWEAK and its cell surface receptor named Fn14 and their role in cancer biology. We reported previously that Fn14 is expressed at low levels in normal lung tissue but highly expressed in many non-small cell lung cancers (NSCLCs). Additionally, in collaboration with Dr. Rosenblum's research group we have successfully developed several Fn14-targeted fusion proteins that exhibit cytotoxic activity on cancer cells in vitro and in vivo. In this Lung Cancer Idea Award application we proposed to test the effects of these fusion proteins, and in particular the GrB-Fc-IT4 construct, on NSCLC cell growth in vitro (Aim 1) and in vivo (Aim 2). During year 1, we were able to demonstrate that two different Fn14-targeted proteins that use granzyme B (GrB) as the cell killing agent (TWEAK-GrB, GrB-Fc-IT4) exhibit pro-apoptotic activity when added to numerous Fn14-positive NSCLC cell lines. During year 2, we conducted additional work to inform the design of the in vivo studies. During our no-cost extension, we worked with Dr. Berens group to test whether the GrB-Fc-IT4 construct could inhibit lung cancer PDX growth in vivo. This data is described in this FINAL REPORT ADDENDUM. During this no-cost extension period we were able to test whether our therapeutic construct GrB-Fc-IT4 could inhibit NSCLC tumor growth in vivo using the NSCLC patient-derived Fn14-positive cell line M2010-1005. The M2010-1005 line was established from a NSCLC patient with a tumor harboring the EGFR del747-752 -activating mutation and, as expected (Whitsett et al., American Journal of Pathology 181:111-120), Fn14 expression is robust in this line (Fig. 1A) . M2010-1005 maintains histological (Fig. 1B) and genetic (unpublished data) characteristics of the original patient tumor during in vivo passaging. Animal experiments to test GrB-Fc-IT4 antitumor efficacy were conducted via subcontract with Dr. Michael Berens at TGen (Phoenix, AZ) following approval by the Institutional Animal Care and Use Committee guidelines of St. Joseph's Hospital and Medical Center. Studies were carried out in nu/nu athymic mice (Jackson Labs) maintained under pathogen-free conditions and a 12-hour light/12-hour dark cycle. Fresh M2010-1005 tumor tissue originally resected from a patient at the time of surgery, with informed, written patient consent, was implanted subcutaneously (s.c.) into the flanks of 6-week-old nu/nu mice. Xenografts were allowed to grow to approximately 200 mm 3 . Animals were grouped randomly (6 mice per group) and treated with vehicle (sterile PBS) or GrB-Fc-IT4 (20 mg/kg) every other day over a ten day period for a total dose of 100 mg/kg via tail vein injection. Tumor size was measured 2-3 times per week by caliper measurements and volumes were calculated using the following formula: V = (a X b2) /2, where 'a' is the largest dimension and 'b' the smallest. Tumor growth in GrB-Fc-IT4-treated animals was compared to vehicle-treated mice. We found that GrB-Fc-IT4 was able to inhibit tumor growth in this lung cancer PDX model (Fig. 2) . was injected subcutaneously into nude mice and tumors were allowed to grow to ~200 mm 3 in volume. Groups (n=6) were injected (iv, tail vein) with either saline (control) or GrB-Fc-IT4 at 20 mg/kg every other day over a ten day period for a total dose of 100 mg/kg. Tumor size was assessed by direct caliper measurements and tumor volumes calculated. Efficacy data is plotted as mean tumor volume +/-SEM.
SUBJECT TERMS
In summary, in this Lung Cancer Idea Award application we proposed to test the effects of new Fn14-targated fusion proteins, and in particular the GrB-Fc-IT4 construct, on NSCLC cell growth in vitro (Aim 1) and in vivo (Aim 2). We have accomplished these goals and more research is in progress. Notably, one of my collaborators on this project, Dr. Michael Rosenblum, has received financial support to begin work that we hope will move the GrB-Fc-IT4 therapeutic agent into a Phase 1 clinical trial (see abstract mentioned below).
Products (Reportable Outcomes from No-Cost Extension):
We have submitted an abstract describing the in vivo results for presentation at a scientific meeting. The meeting information and abstract is on the next page.
